Therapeutic Potential of „Derived-Multiple Allogeneic Proteins Paracrine Signaling-D-Mapps” in the Treatment of Dry Eye Disease

Abstract Dry eye disease (DED) is a chronic inflammatory disease of the lacrimal system and ocular surface. Considering the important role of inflammation in DED development, the main treatment strategy has shifted from hydration and lubrication of dry ocular surface to the immunomodulation and immunoregulationapproach that should address the main pathologic processes responsible for disease progression. Due to their capacity for production of immunosuppressive factors, mesenchymal stem cells (MSCs) and their secretome have been considered as potentially new agents in DED therapy. We recently developed an immunomodulatory ophthalmic solution “derived- Multiple Allogeneic Proteins Paracrine Signaling (d-MAPPS)” which activity is relied on immunosuppressive capacity of MSC-derived secretome. d-MAPPS contains MSC-derived exosomes, growth factors and immunosuppressive cytokines that are able to efficiently suppress generation of inflammatory phenotype in T cells and macrophages. Herewith, we demonstrated that d-MAPPS protected human corneal epithelial cells from chemical injury and efficiently alleviated ocular discomfort and pain in 131 DED patients during the 12-month follow-up, indicating d-MAPPS eye drops as potentially new remedy for the treatment of DED patients.

[1]  N. Arsenijević,et al.  Exo-D-Mapps Attenuates Production of Inflammatory Cytokines and Promoted Generation of Immunosuppressive Phenotype in Peripheral Blood Mononuclear Cells , 2019, Serbian Journal of Experimental and Clinical Research.

[2]  A. Arsenijević,et al.  Therapeutic Potential of “Exosomes Derived Multiple Allogeneic Proteins Paracrine Signaling: Exosomes d-MAPPS” is Based on the Effects of Exosomes, Immunosuppressive and Trophic Factors , 2019, Serbian Journal of Experimental and Clinical Research.

[3]  N. Arsenijević,et al.  Galectin-3 Regulates Indoleamine-2,3-dioxygenase-Dependent Cross-Talk between Colon-Infiltrating Dendritic Cells and T Regulatory Cells and May Represent a Valuable Biomarker for Monitoring the Progression of Ulcerative Colitis , 2019, Cells.

[4]  Jinsong Zhang,et al.  Rebamipide ophthalmic solution modulates the ratio of T helper cell 17/regulatory T cells in dry eye disease mice , 2019, Molecular medicine reports.

[5]  N. Zahr,et al.  Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation , 2019, Drug Safety.

[6]  M. Cifuentes,et al.  Regenerative Therapies in Dry Eye Disease: From Growth Factors to Cell Therapy , 2017, International journal of molecular sciences.

[7]  J. Schuman,et al.  Treg‐recruiting microspheres prevent inflammation in a murine model of dry eye disease , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[8]  K. Tsubota,et al.  TFOS DEWS II Definition and Classification Report. , 2017, The ocular surface.

[9]  M. Milovanovic,et al.  In vitro and in vivo anti-tumor effects of selected platinum(IV) and dinuclear platinum(II) complexes against lung cancer cells , 2017, JBIC Journal of Biological Inorganic Chemistry.

[10]  R. Dana,et al.  T Cell–Derived Granulocyte-Macrophage Colony-Stimulating Factor Contributes to Dry Eye Disease Pathogenesis by Promoting CD11b+ Myeloid Cell Maturation and Migration , 2017, Investigative ophthalmology & visual science.

[11]  Mitchell A Jackson,et al.  Dysfunctional tear syndrome: dry eye disease and associated tear film disorders – new strategies for diagnosis and treatment , 2017, Current opinion in ophthalmology.

[12]  T. Gadek,et al.  Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease , 2016, Clinical ophthalmology.

[13]  Kofi Fred Asiedu,et al.  Ocular Surface Disease Index (OSDI) Versus the Standard Patient Evaluation of Eye Dryness (SPEED): A Study of a Nonclinical Sample , 2016, Cornea.

[14]  L. Marshall,et al.  Treatment of Dry Eye Disease. , 2016, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.

[15]  P. Asbell,et al.  Clinical guidelines for management of dry eye associated with Sjögren disease. , 2015, The ocular surface.

[16]  E. Messmer The pathophysiology, diagnosis, and treatment of dry eye disease. , 2015, Deutsches Arzteblatt international.

[17]  C. König,et al.  Vergleich des OSDI- und SPEED-Fragbogens zur Evaluation des Sicca-Syndroms in der klinischen Praxis , 2014, Der Ophthalmologe.

[18]  P. Asbell,et al.  The Core Mechanism of Dry Eye Disease Is Inflammation , 2014, Eye & contact lens.

[19]  S. Pflugfelder,et al.  T helper cytokines in dry eye disease. , 2013, Experimental eye research.

[20]  O. Lee,et al.  Mesenchymal Stem Cells Tune the Development of Monocyte-Derived Dendritic Cells Toward a Myeloid-Derived Suppressive Phenotype through Growth-Regulated Oncogene Chemokines , 2013, The Journal of Immunology.

[21]  R. Dana,et al.  Dry eye disease: an immune-mediated ocular surface disorder. , 2012, Archives of ophthalmology.

[22]  Hao Wang,et al.  Regulatory T-Cell Generation and Kidney Allograft Tolerance Induced by Mesenchymal Stem Cells Associated With Indoleamine 2,3-Dioxygenase Expression , 2010, Transplantation.

[23]  P. Puccetti,et al.  Gut CD103+ dendritic cells express indoleamine 2,3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction , 2010, Gut.

[24]  R. Dana,et al.  Autoimmunity in Dry Eye Is Due to Resistance of Th17 to Treg Suppression1 , 2009, The Journal of Immunology.

[25]  C. Kim,et al.  Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro , 2004, Clinical & experimental ophthalmology.

[26]  A. Arsenijević,et al.  Molecular Mechanisms Responsible for Anti-inflammatory and Immunosuppressive Effects of Mesenchymal Stem Cell-Derived Factors. , 2019, Advances in experimental medicine and biology.

[27]  A. Arsenijević,et al.  Therapeutic Potential of Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Eye Diseases. , 2018, Advances in experimental medicine and biology.

[28]  S. Schrader,et al.  [Comparison of the OSDI and SPEED questionnaires for the evaluation of dry eye disease in clinical routine]. , 2014, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.